ABN Amro Investment Solutions Has $52.35 Million Stock Holdings in Stryker Corporation $SYK

ABN Amro Investment Solutions trimmed its position in Stryker Corporation (NYSE:SYK) by 16.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 141,616 shares of the medical technology company’s stock after selling 28,265 shares during the quarter. Stryker makes up 1.1% of ABN Amro Investment Solutions’ portfolio, making the stock its 27th biggest position. ABN Amro Investment Solutions’ holdings in Stryker were worth $52,351,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Princeton Global Asset Management LLC lifted its position in Stryker by 16.9% in the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after acquiring an additional 26 shares in the last quarter. Kovack Advisors Inc. grew its holdings in shares of Stryker by 3.6% during the second quarter. Kovack Advisors Inc. now owns 771 shares of the medical technology company’s stock worth $305,000 after buying an additional 27 shares in the last quarter. Armstrong Advisory Group Inc. raised its position in Stryker by 12.3% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 247 shares of the medical technology company’s stock valued at $91,000 after buying an additional 27 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in Stryker by 1.4% in the 3rd quarter. Venturi Wealth Management LLC now owns 1,904 shares of the medical technology company’s stock valued at $704,000 after acquiring an additional 27 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC grew its stake in shares of Stryker by 3.9% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 745 shares of the medical technology company’s stock worth $275,000 after acquiring an additional 28 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their position. The SEC filing for this sale provides additional information. 5.90% of the stock is currently owned by insiders.

Stryker Trading Up 0.0%

Shares of Stryker stock opened at $366.02 on Friday. The firm has a 50-day moving average of $358.00 and a 200-day moving average of $369.35. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $404.87. The stock has a market cap of $140.07 billion, a PE ratio of 43.57, a PEG ratio of 2.14 and a beta of 0.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the previous year, the firm earned $4.01 earnings per share. Stryker’s revenue for the quarter was up 11.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SYK. Sanford C. Bernstein increased their target price on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. BTIG Research raised their price objective on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a report on Friday, January 30th. Evercore set a $390.00 target price on Stryker in a report on Monday, January 5th. Wells Fargo & Company raised their price target on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Finally, Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective for the company in a report on Friday, December 19th. Twelve analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $426.94.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.